tetano
Editor, Senior Moderator
Sci Adv
. 2021 Feb 12;7(7):eabe5054.
doi: 10.1126/sciadv.abe5054. Print 2021 Feb.
INSIGHT: A population-scale COVID-19 testing strategy combining point-of-care diagnosis with centralized high-throughput sequencing
Qianxin Wu[SUP] 1 [/SUP], Chenqu Suo[SUP] 1 2 [/SUP], Tom Brown[SUP] 3 [/SUP], Tengyao Wang[SUP] 4 [/SUP], Sarah A Teichmann[SUP] 5 6 [/SUP], Andrew R Bassett[SUP] 5 [/SUP]
Affiliations
Abstract
We present INSIGHT [isothermal NASBA (nucleic acid sequence-based amplification) sequencing-based high-throughput test], a two-stage coronavirus disease 2019 testing strategy, using a barcoded isothermal NASBA reaction. It combines point-of-care diagnosis with next-generation sequencing, aiming to achieve population-scale testing. Stage 1 allows a quick decentralized readout for early isolation of presymptomatic or asymptomatic patients. It gives results within 1 to 2 hours, using either fluorescence detection or a lateral flow readout, while simultaneously incorporating sample-specific barcodes. The same reaction products from potentially hundreds of thousands of samples can then be pooled and used in a highly multiplexed sequencing-based assay in stage 2. This second stage confirms the near-patient testing results and facilitates centralized data collection. The 95% limit of detection is <50 copies of viral RNA per reaction. INSIGHT is suitable for further development into a rapid home-based, point-of-care assay and is potentially scalable to the population level.
. 2021 Feb 12;7(7):eabe5054.
doi: 10.1126/sciadv.abe5054. Print 2021 Feb.
INSIGHT: A population-scale COVID-19 testing strategy combining point-of-care diagnosis with centralized high-throughput sequencing
Qianxin Wu[SUP] 1 [/SUP], Chenqu Suo[SUP] 1 2 [/SUP], Tom Brown[SUP] 3 [/SUP], Tengyao Wang[SUP] 4 [/SUP], Sarah A Teichmann[SUP] 5 6 [/SUP], Andrew R Bassett[SUP] 5 [/SUP]
Affiliations
- PMID: 33579697
- DOI: 10.1126/sciadv.abe5054
Abstract
We present INSIGHT [isothermal NASBA (nucleic acid sequence-based amplification) sequencing-based high-throughput test], a two-stage coronavirus disease 2019 testing strategy, using a barcoded isothermal NASBA reaction. It combines point-of-care diagnosis with next-generation sequencing, aiming to achieve population-scale testing. Stage 1 allows a quick decentralized readout for early isolation of presymptomatic or asymptomatic patients. It gives results within 1 to 2 hours, using either fluorescence detection or a lateral flow readout, while simultaneously incorporating sample-specific barcodes. The same reaction products from potentially hundreds of thousands of samples can then be pooled and used in a highly multiplexed sequencing-based assay in stage 2. This second stage confirms the near-patient testing results and facilitates centralized data collection. The 95% limit of detection is <50 copies of viral RNA per reaction. INSIGHT is suitable for further development into a rapid home-based, point-of-care assay and is potentially scalable to the population level.